降脂治疗预防静脉血栓栓塞:网络荟萃分析
与安慰剂相比,PCSK9抑制剂联合高强度他汀与VTE风险最大程度降低相关(RR 0.59;95%CI 0.43-0.80),且降脂强度越高,VTE风险降低越明显。
要点
- 高强度他汀单药(RR 0.84)和低/中强度他汀单药(RR 0.89)均显示VTE风险降低趋势。
- 依折麦布单药未影响VTE风险(RR 1.04;95%CI 0.83-1.30)。
核心结论
- 降脂治疗可能具有预防VTE的潜力,尤其在高强度给药和联合治疗时。
- 与低/中强度他汀单药相比,PCSK9抑制剂联合高强度他汀显著更可能降低VTE风险(RR 0.66;95%CI 0.49-0.89)。
研究设计与样本
- 采用加性成分网络荟萃分析比较不同降脂治疗组合对长期随访期间VTE风险的影响。
主要发现
- 与安慰剂相比,PCSK9抑制剂联合高强度他汀与VTE风险最大程度降低相关(RR 0.59;95%CI 0.43-0.80)。
- 高强度他汀单药(RR 0.84;95%CI 0.70-1.02)和低/中强度他汀单药(RR 0.89;95%CI 0.79-1.00)显示VTE风险降低趋势。
- 依折麦布单药未影响VTE风险(RR 1.04;95%CI 0.83-1.30)。
- 随着降脂治疗强度增加,VTE风险降低的汇总效应逐渐增加。
- 与低/中强度他汀单药相比,PCSK9抑制剂联合高强度他汀显著更可能降低VTE风险(RR 0.66;95%CI 0.49-0.89)。
临床怎么用
- 对于VTE高风险患者,可考虑使用高强度他汀或PCSK9抑制剂联合高强度他汀以潜在降低VTE风险。
- 依折麦布单药治疗未显示VTE预防获益,不推荐仅为此目的使用。
- 降脂治疗强度与VTE风险降低相关,临床决策时应综合考虑降脂强度和联合方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Studies have suggested that statins may be associated with reduced risk of venous thromboembolism (VTE). The aim of the current study was to assess the evidence regarding the comparative effect of all lipid-lowering therapies (LLT) in primary VTE prevention. METHODS: After a systematic search of PubMed, CENTRAL, and Web of Science up until 2 November 2022, randomized controlled trials (RCT) of statins (high- or low-/moderate-intensity), ezetimibe, or proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) were selected. An additive component network meta-analysis to compare VTE risk during long-term follow-up across different combinations of LLT was performed. RESULTS: Forty-five RCTs (n = 254 933 patients) were identified, reporting a total of 2084 VTE events. Compared with placebo, the combination of PCSK9i with high-intensity statin was associated with the largest reduction in VTE risk (risk ratio [RR] 0.59; 95% confidence interval [CI] 0.43-0.80), while there was a trend towards reduction for high-intensity (0.84; 0.70-1.02) and low-/moderate-intensity (0.89; 0.79-1.00) statin monotherapy. Ezetimibe monotherapy did not affect the VTE risk (1.04; 0.83-1.30). There was a gradual increase in the summary effect of VTE reduction with increasing intensity of the LLT. When compared with low-/moderate-intensity statin monotherapy, the combination of PCSK9i and high-intensity statin was significantly more likely to reduce VTE risk (0.66; 0.49-0.89). CONCLUSIONS: The present meta-analysis of RCTs suggests that LLT may have a potential for VTE prevention, particularly in high-intensity dosing and in combination therapy.
引用
- Farmakis IT, Christodoulou KC, Hobohm L, et al. Lipid lowering for prevention of venous thromboembolism: a network meta-analysis. Eur Heart J. 2024. PMID: 38874212. doi:10.1093/eurheartj/ehae361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。